An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone who had been trying a tirzepatide-like treatment (they call it “tirz”) for three months posted that it hasn’t helped their weight — in fact, they’ve gained a couple of pounds. They started at lower doses then moved up to higher ones, even skipping a middle dose, but still report no weight loss and ongoing hunger. They say they’re thinking of stopping that drug and going back to semaglutide instead. Tirzepatide is a newer diabetes and weight-loss medication that acts on two appetite-related receptors in the body. In plain terms, it’s a synthetic messenger that tells your brain and gut to reduce hunger and slow digestion; it mixes two signals that normally exist separately. Semaglutide (the active ingredient in Ozempic and Wegovy) is a different drug that mimics one of those natural signals. Both are injected and both can lower appetite and help people lose weight, but they work slightly differently and affect people in different ways. The post is an individual’s experience, not a formal study. That matters because personal stories don’t prove how well a medicine works overall. Clinical trials of tirzepatide have shown substantial average weight loss for many people, but averages hide variation — some people lose a lot, some lose little, and some may gain or plateau for a while. Dose changes, how long someone has been on treatment, diet and activity, other medications, and occasional measurement differences can all affect short-term weight numbers. Three months is relatively early for some weight-loss drugs; also, skipping doses or changing the schedule can blunt effects. Why this matters is practical. If you or someone you know is using these drugs, it’s useful to know that not everyone responds the same way. Seeing little or no change can be frustrating and may mean a reassessment is needed — with a clinician. Switching between tirzepatide and semaglutide is something some people consider because different bodies respond to different drugs. A healthcare provider can help check for reasons a treatment isn’t working, like incorrect dosing, interactions with other medicines, underlying conditions, or issues with adherence. There are important caveats and risks. Personal anecdotes don’t replace medical advice. Both tirzepatide and semaglutide can cause side effects like nausea, diarrhea, or more serious but rarer problems; they’re prescription drugs and not over-the-counter supplements. They’re approved for certain uses and doses, and insurance or a prescriber may limit renewals. Stopping or changing therapy without medical guidance isn’t recommended. If weight isn’t changing, a doctor can run tests and suggest alternatives or adjustments. Bottom line: one person’s early experience with tirzepatide showed no weight loss and prompted thinking about switching back to semaglutide, but that story doesn’t prove how the drugs perform for most people — talk to a clinician to explore why it isn’t working and what to try next.
Source: r/Semaglutide